Post Hoc Analyses of A-SURE and PREVENT Confirm the Effectiveness of rFVIIIFc Prophylaxis Across All Ages, BMIs, Severities, and Inhibitor Histories.
Authors: Oldenburg J, Tiede A, Alamelu J, Álvarez Román MT, Bidlingmaier C, Holme PA, Peyvandi F, Bednar E, Nüesch E, Lethagen S
Journal: TH open : companion journal to thrombosis and haemostasis
anxiety disorders
mental health
open access
Abstract
Approximately 70 million people worldwide live with epilepsy, with around 80% of them residing in low- and middle-income countries (LMICs).
In Brazil, the prevalence rates range from 9.2 to 18.6 per 1,000 individuals.
While most patients manage their condition with antiseizure medications (ASMs), approximately 30 to 40% are refractory, making them potential candidates for surgical treatment. Despite high-level evidence demonstrating the effectiveness and safety of epilepsy surgery for a subset of patients with drug-resistant epilepsy, the procedure remains underutilized, particularly in LMICs.
According to the World Health Organization, epilepsy surgery is available in only 41% of countries globally, and in no more than half of the countries in the Americas. This restricted access contributes to prolonged delays in treatment, negatively affecting quality of life, leading to poorer seizure control, increasing the risk of sudden unexpected death in epilepsy (SUDEP), and imposing a substantial economic burden. Indeed, a recent study showed that, on average, 16.7 years elapse between the diagnosis of epilepsy and the initiation of surgical therapy.
This treatment gap is associated with a 4- to 9-fold increase in hospital care utilization and a 2.1- to 10.6-fold rise in the overall costs of the disease.
In Brazil, the prevalence rates range from 9.2 to 18.6 per 1,000 individuals.
While most patients manage their condition with antiseizure medications (ASMs), approximately 30 to 40% are refractory, making them potential candidates for surgical treatment. Despite high-level evidence demonstrating the effectiveness and safety of epilepsy surgery for a subset of patients with drug-resistant epilepsy, the procedure remains underutilized, particularly in LMICs.
According to the World Health Organization, epilepsy surgery is available in only 41% of countries globally, and in no more than half of the countries in the Americas. This restricted access contributes to prolonged delays in treatment, negatively affecting quality of life, leading to poorer seizure control, increasing the risk of sudden unexpected death in epilepsy (SUDEP), and imposing a substantial economic burden. Indeed, a recent study showed that, on average, 16.7 years elapse between the diagnosis of epilepsy and the initiation of surgical therapy.
This treatment gap is associated with a 4- to 9-fold increase in hospital care utilization and a 2.1- to 10.6-fold rise in the overall costs of the disease.